CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies
Holbrook E K Kohrt, Roch Houot, Matthew Jordan Goldstein et al. · Blood · 2010
Antibody-dependent cell-mediated cytotoxicity (ADCC), which is largely mediated by natural killer (NK) cells, is thought to play an important role in the efficacy of rituximab, an anti-CD20 monoclonal antibody (mAb) used to treat patients with B-cell lymphomas. CD137 is a costimulatory molecule expressed on a variety of immune cells after activation, including NK cells. In the present study, we show that an anti-CD137 agonistic mAb enhances the antilymphoma activity of rituximab by enhancing ADCC. Human NK cells up-regulate CD137 after encountering rituximab-coated tumor B cells, and subsequent stimulation of these NK cells with anti-CD137 mAb enhances rituximab-dependent cytotoxicity against the lymphoma cells. In a syngeneic murine lymphoma model and in a xenotransplanted human lymphoma model, sequential administration of anti-CD20 mAb followed by anti-CD137 mAb had potent antilymphoma activity in vivo. These results support a novel, sequential antibody approach against B-cell malignancies by targeting first the tumor and then the host immune system.
Cited by 205 works. doi:10.1182/blood-2010-08-301945 Open-access PDF
Authors
- Holbrook E K Kohrt
- Roch Houot
- Matthew Jordan Goldstein
- Kipp Weiskopf
- Ash A. Alizadeh
- Josh Brody
- Antonia M. S. Müller
- Russell Kent Pachynski
- Debra Katherine Czerwinski
- Steven E. Coutre
- Mark Ping Chao
- Lieping Chen
- Thomas F. Tedder
- Ronald Levy
References
- Cancer Statistics, 2009
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
- Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
- Immunostimulatory monoclonal antibodies for cancer therapy
- The biology of human natural killer-cell subsets
- IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma.
- Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
- Biology of the human malignant lymphomas. IV. Functional characterization of ten diffuse histiocytic lymphoma cell lines